By Daniella
Nanox (Nasdaq: NNOX), received FDA clearance to produce tomographic images for broader diagnostic applications, the company said.
Nanox.ARC, now deployed in healthcare facilities across seven U.S. states, utilize proprietary tomosynthesis technology with a cold cathode, the system delivers detailed 3D imaging, improving visualization and reducing limitations of traditional 2D X-rays, the company said.
“With this FDA clearance, we can now offer U.S. healthcare providers significantly broader imaging capabilities that are akin to commonly used traditional X-ray devices,” said Erez Meltzer, Nanox Chief Executive Officer and Acting Chairman. “Our mission is to provide healthcare practices with a transformative imaging advantage with the Nanox.ARC – an accessible, cost-effective solution that not only provides advanced diagnostic imaging capabilities but also elevates overall patient care.”
